Loyal Valley Capital
China's DP Technology raises $97m
China’s DP Technology, touted as a pioneer in the use of artificial intelligence (AI) for scientific research, has raised a CNY 700m (USD 97m) round featuring Loyal Valley Capital.
Deal focus: Medilink chases global ADC opportunity
The Medilink Therapeutics team spun out from Kelun-Biotech to develop antibody drug conjugates capable of competing with the world’s best. Its USD 70m Series B will support the pursuit of this goal
Lyfe, Qiming lead Series B for China ADC player Medilink
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised a USD 70m Series B led by Lyfe Capital and Qiming Venture Partners.
China’s ABclonal Technology raises $189m
Chinese life science research and diagnostic reagents provider ABclonal Technology has raised a RMB1.2 billion ($189 million) Series D round featuring Sequoia Capital China.
NetEase music spinout completes $449m Hong Kong IPO
Cloud Village, a music streaming business controlled by Chinese internet giant NetEase and backed by several private equity investors, has raised HK$3.5 billion ($449 million) through a Hong Kong IPO.
China CRO Tripod raises $156m
Tripod Preclinical Research Laboratories, a China-based contract research organization (CRO) based in Nanjing, has raised RMB1 billion ($156 million) led by Ruihua Capital, Lilly Asia Ventures (LAV) and GL Ventures.
China vaccine developer Abogen raises $700m
Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, has raised $700 million in Series C funding featuring Temasek Holdings, Loyal Valley Capital, and Lilly Asia Ventures.
Netease to spin out PE-backed music streaming business
Cloud Village, a music streaming business controlled by Chinese internet and gaming giant NetEase and backed by the likes of General Atlantic, Boyu Capital, and Yunfeng Capital, has filed for a Hong Kong IPO.
Loyal Valley leads Series B extension for China's Edigene
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.
Deal focus: Loyal Valley realizes $600m from the Bilibili show
Chinese video-streaming platform Bilbili has won the hearts, minds, and wallets of users amid an intensifying content-based battle. Loyal Valley Capital picked an opportune time to make a partial exit
Loyal Valley leads Series B for China vision therapy start-up
China-based eye disorder specialist Arctic Vision has raised a $100 million Series B round led by Loyal Valley Capital. Tencent Holdings, Octagon Capital, and New World Development CEO Adrian Cheng also participated.
VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
China’s Regor Therapeutics raises $90m Series B
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.
PE-backed Pop Mart posts strong gain after $674m HK IPO
Pop Mart International Group, China’s largest fashion toy retailer, gained 79% on its Hong Kong trading debut following a HK$5.22 billion ($674 million) IPO.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
China's JW Therapeutics trades up after $300m Hong Kong IPO
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
China's CARsgen raises $186m Series C
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
Lee's Pharmaceutical spin-out gets $145m Series B
Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO), a subsidiary of Lee’s Pharmaceutical, has raised a $145 million Series B round led by Hillhouse Capital and TPG Asia.
PE-backed Junshi Biosciences shines on Star Market debut
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
China IPOs: Star attraction
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations
CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
PE-backed Chinese pop toy retailer pursues Hong Kong IPO
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
Shiyu leads $276m round for China's Mabwell Biotech
Mabwell Biotech, a Chinese drug developer with one treatment cleared for production, has raised RMB1.97 billion ($276 million) in Series A funding across two tranches led by specialist healthcare investor Shiyu Capital.